Peer-reviewed veterinary case report
Transdermal methimazole lowers thyroid hormone in cats
By Lécuyer, Manon et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2006·Faculty of Veterinary Medicine, Canada·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism.
- Species:
- cat
Plain-English summary
Thirteen cats with newly diagnosed hyperthyroidism were treated with a skin medication called transdermal methimazole, applied to their ears twice a day for 28 days. After treatment, all cats showed improvement, with their thyroid hormone levels dropping significantly. Most cats tolerated the treatment well, although one cat experienced a skin reaction and low platelet levels. Overall, transdermal methimazole proved to be an effective and safe option for managing hyperthyroidism in cats.
People also search for: cat hyperthyroidism treatment · transdermal methimazole for cats · symptoms of hyperthyroidism in cats
Abstract
Thirteen cats, newly diagnosed with hyperthyroidism, were treated with a transdermal formulation of methimazole at a dose of 5 mg (0.1 mL) (concentration of 50 mg/mL) applied to the internal ear pinna every 12 h for 28 d. Baseline hematologic and biochemical values, along with serum thyroxine (T4) levels, were obtained on presentation (day 0). Cats were evaluated at 14 d (D14) and 28 d (D28) following transdermal therapy. At each visit, a physical examination, a complete blood cell count, a serum biochemical analysis, and a serum T4 evaluation were performed. Ten cats completed the study. Clinical improvement, as well as a significant decrease in T4, was noted in all cats. Serum T4 measured at D14 and D28 were significantly lower at 27.44 nmol/L, s = 37.51 and 14.63 nmol/L, s = 10.65, respectively (P < 0.0001), as compared with values at D0 (97.31 nmol/L, s = 37.55). Only 1 cat showed a cutaneous adverse reaction along with a marked thrombocytopenia. The results of this prospective clinical study suggest that transdermal methimazole is an effective and safe alternative to conventional oral formulations.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16579038/